Acer Therapeutics Inc.
ACER evidence brief
What we can confirm
- BioSniper Score:
- 8.0 / 10
- Lead Asset:
- acer-801 (Phase 2)
What it means
What to watch
Prepared research question
What matters most for ACER—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
acer-801 (Phase 2)
Next Catalyst
—
Tracking 3 pipeline candidates · 1 clinical trial · 1 FDA decision for Acer Therapeutics Inc..
Run Acer Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Acer Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Approved
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Governance
Frequently asked questions
What is Acer Therapeutics Inc.'s lead drug candidate?
Acer Therapeutics Inc.'s most advanced tracked candidate is acer-801 (Phase 2) for Vasomotor symptoms (VMS), post-traumatic stress disorder (PTSD), and prostate cancer.
Who is the CEO of Acer Therapeutics Inc.?
Schelling Founder is the chief executive officer of Acer Therapeutics Inc. (ACER).
What therapeutic areas does Acer Therapeutics Inc. focus on?
Acer Therapeutics Inc. develops therapies across Oncology, Rare Disease, Neurology, Ophthalmology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.